Related Experiment Videos
Three germline mutations in the TP53 gene
R S Cornelis1, M van Vliet, M J van de Vijver
1Department of Human Genetics, University of Leiden, The Netherlands.
Abstract:
Three germline mutations in the TP53 tumor-suppressor gene are reported, two of which are not reported previously. A missense mutation at codon 265 of TP53 was found in three patients of a family that complied with the definition of the Li-Fraumeni syndrome. A nonsense mutation in codon 306 was found in a woman who had had a rhabdomyosarcoma at age 4 and a subsequent breast cancer at age 22. She was part of a Li-Fraumeni-like family, but the parental origin of the mutation could not be traced. Finally, while screening for somatic alterations in TP53 in a series of 141 sporadic breast tumors, we detected a constitutional missense mutation in codon 235 in a woman diagnosed with breast cancer at age 26 and a recurrence 4 years later. The recurrence, but not the primary tumor, showed an additional missense mutation at codon 245 as well as loss of the wild-type allele. This suggests that the 245 mutation was particularly important for tumor progression and that there might exist heterogeneity in terms of cancer predisposition potential among the various germline TP53 mutations.
Insights
This study identifies novel germline mutations in the TP53 tumor-suppressor gene, linked to Li-Fraumeni syndrome and sporadic breast cancers. These findings highlight the diverse roles of TP53 mutations in cancer predisposition and progression.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- The TP53 gene is a critical tumor suppressor involved in maintaining genomic stability.
- Germline mutations in TP53 are associated with Li-Fraumeni syndrome, a rare inherited cancer predisposition disorder.
- Understanding TP53 mutations is crucial for cancer risk assessment and therapeutic strategies.
Purpose of the Study:
- To report novel germline mutations in the TP53 gene.
- To investigate the association of these mutations with Li-Fraumeni syndrome and sporadic breast cancer.
- To explore the role of specific TP53 mutations in tumor progression.
Main Methods:
- Germline DNA sequencing to identify TP53 mutations.
- Analysis of TP53 mutations in familial cancer cases and sporadic breast tumors.
- Genomic analysis of tumor samples to detect additional mutations and loss of heterozygosity.
Main Results:
- Three germline TP53 mutations were identified, two previously unreported.
- A missense mutation at codon 265 was found in a Li-Fraumeni syndrome family.
- A constitutional missense mutation at codon 235 and a secondary mutation at codon 245 were identified in a breast cancer patient, with the latter associated with tumor progression.
Conclusions:
- Novel germline TP53 mutations contribute to cancer predisposition, including Li-Fraumeni syndrome.
- Specific TP53 mutations, like the one at codon 245, may play a significant role in tumor progression.
- There is likely heterogeneity in cancer predisposition potential among different germline TP53 mutations.